Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Forteo-Generic (teriparatide) is a parathyroid hormone analog, (PTH 1-34), which is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Brand Name : Forteo-Generic
Molecule Type : Peptide
Upfront Cash : Not Applicable
December 01, 2023
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Recipient : Apotex Fermentation Inc.
Deal Size : Not Applicable
Deal Type : Not Applicable
Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States
Details : Teriparatide Injection, a single-patient-use pre-filled pen and a parathyroid hormone analog, is used for the treatment of osteoporosis in the United States.
Brand Name : Teriparatide-Generic
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 21, 2023
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Recipient : Apotex Fermentation Inc.
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?